NCT03132324View on ClinicalTrials.gov

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

October 3, 2018

Study Completion Date

October 3, 2018

Conditions
Sickle Cell Disease
Interventions
DRUG

INCB059872

INCB059872 tablets

Trial Locations (7)

23298

Virginia Commonwealth University, Richmond

33142

Acevedo Clinical Research Associates, Miami

33147

Advanced Pharma, Miami

33319

Vita Health and Medical Center, Tamarac

53226

Blood Centers of Wisconsin, Milwaukee

60607

University of Illinois at Chicago, Chicago

02215

Boston University, Boston

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY